NASDAQ:JAGX - Jaguar Health Stock Price, Forecast & News

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Jaguar Health Inc (NASDAQ:JAGX) announced its quarterly earnings data on Monday, November, 14th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.10. The biotechnology company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.10 million. Jaguar Health had a negative net margin of 771.25% and a negative return on equity of 675.03%. View Jaguar Health's Earnings History.

Jaguar Health is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Jaguar Health.

2 brokers have issued 1 year price targets for Jaguar Health's stock. Their forecasts range from $3.00 to $5.00. On average, they expect Jaguar Health's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 488.2% from the stock's current price. View Analyst Price Targets for Jaguar Health.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jaguar Health.

News headlines about JAGX stock have trended neutral on Monday, InfoTrie reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Jaguar Health earned a news impact score of 0.4 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Jaguar Health.

Some companies that are related to Jaguar Health include Galectin Therapeutics (GALT), Aldeyra Therapeutics (ALDX), PhaseBio Pharmaceuticals (PHAS), CELYAD SA/ADR (CYAD), Sierra Oncology (SRRA), IDEAYA Biosciences (IDYA), Newron Pharmaceuticals (NWPHF), NeuBase Therapeutics (NBSE), Cassava Sciences (SAVA), Galmed Pharmaceuticals (GLMD), ProMetic Life Sciences (PFSCF), Menlo Therapeutics (MNLO), Cyclerion Therapeutics (CYCN), Aravive (ARAV) and TapImmune (MRKR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biopharmx (BPMX), Conatus Pharmaceuticals (CNAT), Cara Therapeutics (CARA), Precipio (PRPO), Neovasc (NVCN), PTC Therapeutics (PTCT), Biocept (BIOC), Cascadian Therapeutics (CASC), Cellectar Biosciences (CLRB) and SCYNEXIS (SCYX).

(JAGX) raised $22 million in an initial public offering (IPO) on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Jaguar Health's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.21%). Company insiders that own Jaguar Health stock include James J Bochnowski, Jonathan B Siegel, Lisa A Conte and Nantucket Investments Ltd. View Institutional Ownership Trends for Jaguar Health.

JAGX stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Jaguar Health stock in the last two years include James J Bochnowski, Jonathan B Siegel and Lisa A Conte. View Insider Buying and Selling for Jaguar Health.

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of JAGX stock can currently be purchased for approximately $0.68.

Jaguar Health has a market capitalization of $34.78 million and generates $4.42 million in revenue each year. The biotechnology company earns $-32,150,000.00 in net income (profit) each year or ($158.74) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.View Additional Information About Jaguar Health.

The official website for Jaguar Health is http://www.jaguaranimalhealth.com/.

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.